Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep48 | Adrenal cortex | ECE2015

The treatment with ‘dual release' hydrocortisone (DR-HC) in congenital adrenal hyperplasia: short-term (6 months) and long-term (12 months) follow-up after the switch from conventional glucocorticoids to DR-HC

Simeoli Chiara , De Martino Maria Cristina , Iacuaniello Davide , Mannarino Teresa , Cozzolino Alessia , De Leo Monica , Pivonello Claudia , Negri Mariarosaria , De Angelis Cristina , Colao Annamaria , Pivonello Rosario

In patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, life-long glucocorticoid (GC) treatment is often required to replace cortisol deficiency and to avoid the ACTH-dependent androgen levels increase. However, in these patients, the multiple daily doses required with conventional GCs can cause cortisol overexposure, leading to an increased risk of metabolic syndrome (MS), an impaired quality of life (QoL), and poor treatment compliance (TC). T...

ea0035p29 | Adrenal cortex | ECE2014

The treatment with glucocorticoids in congenital adrenal hyperplasia: short- and long-term effects of the switch from conventional glucocorticoids to ‘dual release' hydrocortisone on metabolic and hormonal profile

Simeoli Chiara , Mannarino Teresa , De Martino Maria Cristina , Cozzolino Alessia , Iacuaniello Davide , De Leo Monica , Auriemma Renata S , Di Somma Carolina , Colao Annamaria , Pivonello Rosario

Life-long glucocorticoid (GC) treatment is needed in patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency in order to replace cortisol deficiency and to control ACTH and consequently androgen levels. Therefore, patients with CAH tend to have an increased risk of metabolic syndrome (MS), probably due to cortisol overexposure, caused by multiple daily doses of conventional GCs, unable to mimic cortisol circadian rhythm. The current study aimed at i...